Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 2Phase 4 1Phase 3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Breast Neoplasms 49Neoplasms 36Prostatic Neoplasms 25Carcinoma, Non-Small-Cell Lung 25Polycystic Ovary Syndrome 16Pain 15Keratosis, Actinic 14Leukemia 12Colorectal Neoplasms 11Uterine Cervical Neoplasms 10Pancreatic Neoplasms 10Lung Neoplasms 10Leiomyoma 10Carcinoma, Hepatocellular 10Ovarian Neoplasms 9Neoplasm Metastasis 9Lymphoma, Follicular 9Carcinoma, Renal Cell 9Brain Neoplasms 9Neuroendocrine Tumors 8Arthritis, Rheumatoid 8Precursor Cell Lymphoblastic Leukemia-Lymphoma 7Melanoma 7Kidney Neoplasms 7Head and Neck Neoplasms 7Colonic Neoplasms 7Cancer Pain 7Multiple Myeloma 6Lymphoma 6Liver Neoplasms 6

Interventions

Inotuzumab Ozogamicin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 4 × Has results × Precursor B-Cell Lymphoblastic Leukemia-Lymphoma × Clear all
NCT03677596 2023-11-22

A Study Of Two Inotuzumab Ozogamicin Doses in Relapsed/ Refractory Acute Lymphoblastic Leukemia Transplant Eligible Patients

Pfizer

Phase 4 Completed
102 enrolled 27 charts
LymphoidOther hematologic neoplasm

Leukemia, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡